Journal Updates
eMediNexus Coverage from: 
Better progression-free survival with ibrutinib regimens in untreated older CLL patients
eMediNexus,  01 January 2019
remove_red_eye 3939 Views
#Hematology #Hospital Medicine #Oncology

0 Read Comments                

Treatment with ibrutinib was superior to treatment with bendamustine plus rituximab with regard to progression-free survival among older patients with untreated chronic lymphocytic leukemia (CLL). The study published December 27, 2018 in the New England Journal of Medicine found no significant difference between ibrutinib and ibrutinib plus rituximab with regard to progression-free survival.
To continue reading this article
Sign in with Medtalks

Continue reading your article with a eMediNexus account.
Free Membership!